- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06096779
절제 불가능한 간세포 암종 및 Child-Pugh B7 및 B8 간경변증 환자에서 베바시주맙 유무에 관계없이 아테졸리주맙을 평가하는 연구 (Kirros)
절제 불가능한 간세포암종 및 Child-Pugh B7 및 B8 간경변증 환자를 대상으로 한 제2상, 공개, 다중 코호트, 다기관 연구
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
연구 개요
상세 설명
This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Arizona
-
Tucson, Arizona, 미국, 85724
- University of Arizona Cancer Center
-
-
California
-
La Jolla, California, 미국, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, 미국, 90089-5601
- University of Southern California-Keck School of Medicine -1975 Zonal Ave
-
Newport Beach, California, 미국, 92663
- University of Southern California
-
Orange, California, 미국, 92868
- University of California Irvine Medical Center
-
Pasadena, California, 미국, 91105-2561
- California Liver Research Institute
-
Sacramento, California, 미국, 95817
- University of California Davis Medical Center
-
Stanford, California, 미국, 94305
- Stanford Health Care
-
Torrance, California, 미국, 90502-2006
- Harbor UCLA Medical Center
-
West Hollywood, California, 미국, 90048-2422
- Cedars Sinai Comprehensive Transplant Center
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- Hartford Healthcare Cancer Institute at Hartford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20037
- George Washington University- Medical Faculty Associates
-
Washington D.C., District of Columbia, 미국, 20422-0001
- Washington DC VA Medical Center
-
-
Florida
-
Orlando, Florida, 미국, 32806
- Orlando Health Inc.
-
-
Illinois
-
Chicago, Illinois, 미국, 60611-2908
- Northwestern University
-
Chicago, Illinois, 미국, 60612-4795
- University of Illinois Health Outpatient Care Center
-
Chicago, Illinois, 미국, 60637-1426
- The Duchossois Center for Advanced Medicine
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536-7001
- University of Kentucky - Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70805
- LSU Health Baton Rouge
-
Baton Rouge, Louisiana, 미국, 70808-4300
- Our Lady of the Lake Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, 미국, 02111
- Tufts Medical Center
-
-
Michigan
-
Detroit, Michigan, 미국, 48201
- Barbara Ann Karmanos Cancer Institute
-
Detroit, Michigan, 미국, 48202
- Henry Ford Health System
-
-
Missouri
-
Kansas City, Missouri, 미국, 64111
- Saint Luke?s Hospital of Kansas City
-
-
New Jersey
-
New Brunswick, New Jersey, 미국, 08901
- Rutgers Cancer Institute of New Jersey
-
Newark, New Jersey, 미국, 07103
- Rutgers Cancer Institute of New Jersey at University Hospital
-
-
New York
-
Mineola, New York, 미국, 11501-4064
- NYU Langone Hospital - Long Island
-
New York, New York, 미국, 10029
- Icahn School of Medicine at Mount Sinai
-
The Bronx, New York, 미국, 10467
- Montefiore Medical Center
-
The Bronx, New York, 미국, 10468-3904
- James J Peters Veterans Administration Medical Center - NAVREF
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28204
- Levine Cancer Institute
-
-
Ohio
-
Dayton, Ohio, 미국, 45428-9000
- Dayton VA Medical Center - NAVREF - PPDS
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104-5020
- The University of Oklahoma Health Sciences Center
-
-
Oregon
-
Hillsboro, Oregon, 미국, 97124-5806
- Kaiser Permanente Westside Medical Center
-
Portland, Oregon, 미국, 97239-3011
- OHSU Knight Cancer Institute Hematology Oncology
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107
- Jefferson Health Honickman Center
-
Pittsburgh, Pennsylvania, 미국, 15240
- Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
-
-
Tennessee
-
Germantown, Tennessee, 미국, 38138-1762
- The West Clinic (East Campus)
-
Nashville, Tennessee, 미국, 37208-2918
- Nashville General Hospital at Meharry
-
-
Texas
-
Dallas, Texas, 미국, 75390-0001
- University of Texas Southwestern Medical Center
-
Dallas, Texas, 미국, 75246-2008
- Texas Oncology (Worth) - USOR
-
Dallas, Texas, 미국, 75203-1260
- Liver Institute at Methodist Dallas
-
Dallas, Texas, 미국, 75235
- Moody Outpatient Center ? Parkland Health
-
Denison, Texas, 미국, 75020-0084
- Texas Oncology - Denison Cancer Center
-
Houston, Texas, 미국, 77025-1669
- Kelsey Research Foundation
-
Houston, Texas, 미국, 77030-4211
- Michael E Debakey VA Medical Center - NAVREF - PPDS
-
-
Utah
-
Murray, Utah, 미국, 84107-5741
- Intermountain Healthcare
-
St. George, Utah, 미국, 84790
- Intermountain Cancer Center
-
-
Virginia
-
Falls Church, Virginia, 미국, 22042
- Inova Schar Cancer Institute
-
Richmond, Virginia, 미국, 23226-1925
- Bon Secours St. Mary's Hospital
-
Richmond, Virginia, 미국, 23298-5028
- VCU Medical Center North Hospital
-
-
Washington
-
Seattle, Washington, 미국, 98101
- Virginia Mason Medical Center
-
-
-
-
-
Rio Piedras, 푸에르토 리코, 00935
- Pan American Center for Oncology Trials, LLC
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
General Inclusion Criteria:
- Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
- Disease that is not amenable to curative surgical and/or locoregional therapies
- No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
- Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment
- Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment
- Adequate hematologic and end-organ function
- Life expectancy of at least 12 weeks
- Female participants of childbearing potential must be willing to avoid pregnancy and egg donation
- Absolute neutrophil count (ANC) ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support
- Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion
- Hemoglobin (Hb) ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)
- Serum bilirubin ≤ 3 × ULN
- Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
- Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months
- International normalized ratio (INR) ≤2.3
General Exclusion Criteria:
- Pregnancy or breastfeeding
- Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
- Treatment with systemic immunostimulatory agents
- Treatment with systemic immunosuppressive medication
- Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
- Inadequately controlled hypertension
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation
- Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded
- Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- Prior allogeneic stem cell or solid organ transplantation
- Actively listed for liver transplantation
- Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
- Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment
- Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment
- History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B
- Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.
- Participants with ascites controlled on diuretics are allowed
- History of spontaneous bacterial peritonitis within last 12 months
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort A: Atezolizumab+Bevacizumab
Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
다른 이름들:
Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.
다른 이름들:
|
|
실험적: Cohort B: Atezolizumab
Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator. |
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants With Adverse Events (AEs)
기간: Baseline through the end of the study (up to approximately 36 months)
|
An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B. |
Baseline through the end of the study (up to approximately 36 months)
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Clinical Trials, Hoffmann-La Roche
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- ML44719
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .